Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

26°
- Kane, PA (16735)
  Today
  
  Partly cloudy skies this evening will become overcast overnight. Low 22F. Winds SW at 10 to 15 mph..
  
  Tonight
  
  Partly cloudy skies this evening will become overcast overnight. Low 22F. Winds SW at 10 to 15 mph.
  
  Updated: December 16, 2025 @ 4:27 pm
- Full Forecast

Site search

Home
News
Sports
Obituaries
Local Events
- Promote Your Event
Photos
e-Edition
Classifieds
- Place an ad
Archives

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Tiziana Life Sciences Ltd.

< Previous 1 2 3 4 Next >

Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023

April 20, 2023

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes

April 18, 2023

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID

April 13, 2023

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai

April 10, 2023

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference

April 04, 2023

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage

April 04, 2023

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in

March 31, 2023

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)

March 28, 2023

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO

March 22, 2023

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO

March 21, 2023

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO

March 20, 2023

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO

March 17, 2023

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Highlighted in Forbes Article

March 17, 2023

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal Foralumab

March 08, 2023

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer

January 04, 2023

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab

January 03, 2023

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Updated Interim Results for the Six Months Ended 30 June 2022

December 29, 2022

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Interim Results for the Six Months Ended 30 June 2022

December 27, 2022

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana to Participate in January Investor Meetings

December 16, 2022

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study

December 15, 2022

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Ltd. Granted 180-day Extension by Nasdaq to Meet Minimum Bid Price Requirements

December 14, 2022

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Announces Date of Annual General Meeting 2022

December 06, 2022

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human Subjects

November 23, 2022

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)

November 10, 2022

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences to Host Investor Call

November 04, 2022

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman

November 03, 2022

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

November 02, 2022

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

October 26, 2022

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference

October 19, 2022

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

Tiziana Life Sciences Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients

October 12, 2022

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tickers TLSA

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Entertainment
Local Events
Obituaries
Multimedia
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

The Kane Republican

KaneRepublican.com
200 North Fraley
Kane, PA 16735
Phone: 814-837-6000
Email: krnews1@zitomedia.net

Facebook

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Kane, PA (16735)

Today

Tonight

Articles published by Tiziana Life Sciences Ltd.

Sections

Services

The Kane Republican